On this page
Key takeaways
• Fisetin has broad anti-inflammatory activity in cell and animal models across NF-κB suppression, IL-6/TNF-α reduction, and SASP suppression (1,4).
• One active human trial tests fisetin for osteoarthritis — NCT04210986, testing pulsed fisetin for cartilage degeneration (2). Not yet reported.
• The AFFIRM trial includes systemic inflammatory markers as secondary endpoints — IL-6, TNF-α, hs-CRP — in frail post-menopausal women (7).
• Preclinical evidence for osteoarthritis is coherent — Zheng 2017 showed fisetin inhibited IL-1β-induced inflammation in human chondrocytes and attenuated OA progression in mice (3).
• Mast cell activation and allergic conditions have anecdotal support but limited controlled evidence. Quercetin has stronger anti-mast-cell evidence (6).
• Fisetin is not a substitute for prescribed anti-inflammatory therapy in autoimmune, rheumatological, or moderate-to-severe joint disease.
Quick answer
Fisetin has broad anti-inflammatory activity in preclinical models — suppressing NF-κB signalling, reducing production of IL-6, TNF-α, and IL-1β, and clearing senescent cells that drive chronic inflammatory signalling (inflammaging) (1,4,8). Preclinical evidence for osteoarthritis is coherent and includes both cell culture and mouse in vivo data (3). One human trial (NCT04210986) is testing fisetin specifically for cartilage degeneration in osteoarthritis (2); it has not reported. The AFFIRM trial includes systemic inflammatory markers as secondary endpoints (7). Fisetin is used anecdotally for mast cell activation syndrome (MCAS), allergic inflammation, and general inflammatory joint pain in the longevity community, but the human evidence for these specific indications is limited. Fisetin should not substitute for prescribed anti-inflammatory therapy in autoimmune or moderate-to-severe joint disease. For the full context, see our complete clinician’s guide.
The broad anti-inflammatory case
Fisetin’s anti-inflammatory identity is broadly established in cell and animal models. Three distinct mechanisms contribute.
NF-κB pathway suppression
NF-κB is the master transcription factor driving the expression of most pro-inflammatory cytokines. Fisetin suppresses NF-κB activation in multiple cell types, including macrophages, microglia, chondrocytes, and endothelial cells (4). The result is reduced production of IL-6, TNF-α, IL-1β, and other inflammatory mediators. This is a general anti-inflammatory mechanism shared with the broader flavonoid class.
SASP suppression in senescent cells
The senolytic story extends to inflammation. Senescent cells that accumulate with age secrete SASP factors that drive chronic low-grade systemic inflammation — the phenomenon called "inflammaging" (8). Clearing senescent cells reduces the SASP output; fisetin’s senolytic activity therefore reduces inflammation indirectly by removing the cells producing it (1). This is a mechanism distinct from direct anti-inflammatory activity.
Nrf2 activation
Nrf2 pathway activation upregulates endogenous antioxidant defences, which reduces oxidative stress-driven inflammatory signalling. This contributes to fisetin’s anti-inflammatory profile in tissues under oxidative pressure — UV-exposed skin, ischaemic tissue, chronically inflamed joints.
Osteoarthritis — the active trial
Osteoarthritis is the fisetin inflammation indication with the strongest current attention. The disease involves cartilage degeneration driven partly by senescent cell accumulation in the joint tissue and partly by chronic low-grade inflammatory signalling from surrounding synovium. The mechanistic case for a senolytic anti-inflammatory intervention is particularly strong.
Zheng 2017 — preclinical anchor
Zheng and colleagues (Int Immunopharmacol, 2017) tested fisetin in human osteoarthritis chondrocytes exposed to IL-1β (a key inflammatory mediator in OA) (3). Fisetin suppressed IL-1β-induced inflammation, activated SIRT1 signalling, and preserved chondrocyte function. In vivo, fisetin attenuated OA progression in a surgical mouse model. This is coherent preclinical evidence for a joint-tissue anti-inflammatory effect.
NCT04210986 — the active human trial
The Mayo Clinic OA cartilage trial (NCT04210986) is testing pulsed fisetin in adults with knee osteoarthritis (2). The primary endpoints include cartilage integrity by imaging and joint symptom scores. The trial uses the standard 20 mg/kg × 2 days pulsed protocol. It has been recruiting for several years. When it publishes, it will be the first randomised evidence for or against fisetin’s clinical benefit in OA. Until then, the OA case is preclinically supported but clinically pending.
Mast cell activation syndrome (MCAS) and allergies
A specific and increasingly discussed indication in the longevity community. MCAS is characterised by inappropriate mast cell activation producing symptoms across multiple systems — flushing, GI upset, chronic hives, headaches, brain fog. Both fisetin and quercetin have been proposed as natural anti-mast-cell interventions.
The evidence base for quercetin in mast cell disease is stronger than for fisetin — Weng and colleagues (2012) demonstrated that quercetin is more effective than cromolyn (a prescription mast cell stabiliser) at blocking human mast cell cytokine release in cell culture (6). Fisetin has been anecdotally used in MCAS management, often combined with quercetin, but does not have equivalent published human evidence. If mast cell modulation is your specific goal, quercetin is the flavonoid with more direct evidence. Our fisetin vs quercetin article covers this comparison.
Allergic inflammation
Molina and colleagues (2020) reported that fisetin reduced the acute phase of UVB-induced allergic contact dermatitis in mice (5). Fisetin has been broadly studied for allergic inflammatory conditions with generally positive preclinical results. Human trial data for allergic rhinitis, atopic dermatitis, or asthma with fisetin specifically are limited. Patients with these conditions should continue prescribed treatment; fisetin is a possible adjunct with a modest anti-inflammatory contribution.
The AFFIRM inflammatory endpoints
The AFFIRM trial includes systemic inflammatory markers as secondary endpoints — IL-6, TNF-α, hs-CRP — in the pulsed fisetin protocol in frail post-menopausal women (7). When AFFIRM publishes, it will provide the first randomised evidence for whether fisetin at trial doses reduces systemic inflammatory tone in humans. This will be relevant to the general anti-inflammatory case even beyond the primary frailty endpoint.
What fisetin is not appropriate for
Fisetin’s anti-inflammatory activity is modest at supplement doses and is not a substitute for prescribed therapy in serious inflammatory conditions.
• Rheumatoid arthritis, psoriatic arthritis, and other autoimmune joint diseases require DMARDs and biologics. Fisetin does not substitute.
• Acute inflammatory conditions requiring prescription NSAIDs, corticosteroids, or opiate analgesia should not be managed with fisetin alone.
• Moderate to severe osteoarthritis with functional impairment should be managed by rheumatology or orthopaedics with evidence-based treatment. Fisetin is a possible adjunct at best.
• Systemic inflammatory conditions (systemic lupus erythematosus, vasculitis, systemic inflammatory response syndrome) require prescribed immunomodulation. Fisetin does not substitute.
Practical guidance
For readers considering fisetin specifically for inflammatory or joint indications:
• Continue any prescribed anti-inflammatory therapy and discuss fisetin as a possible adjunct with your prescriber.
• Track hs-CRP before and after 3–6 months of fisetin as a personal marker of systemic inflammatory tone. This is the closest available surrogate to what AFFIRM is measuring.
• For MCAS or allergic inflammation specifically, quercetin has more direct evidence than fisetin. Combined use is a reasonable approach.
• For osteoarthritis specifically, the ongoing NCT04210986 trial is the load-bearing pending evidence. Reasonable to explore fisetin as an adjunct while continuing standard OA management.
• The pulsed protocol is more likely to reach anti-inflammatory tissue concentrations than continuous daily dosing. See our dedicated pulse dosing article.
What we still don't know
• Whether fisetin at supplement doses reduces measurable inflammatory markers in humans. AFFIRM will be the first randomised test.
• Whether the OA cartilage trial (NCT04210986) will demonstrate clinical benefit — result timeline unknown.
• Whether fisetin combined with quercetin produces additive anti-mast-cell effects in humans. Not tested in a controlled trial.
• Which joint-tissue concentrations of fisetin are achievable at supplement doses. Not directly measured in humans.
• Whether fisetin interacts meaningfully with NSAIDs, corticosteroids, or DMARDs. No formal interaction studies exist.
Bottom line
Fisetin has broad preclinical anti-inflammatory activity across multiple mechanisms (NF-κB suppression, SASP suppression, Nrf2 activation) and coherent preclinical evidence for osteoarthritis specifically. One active human trial is testing fisetin for cartilage degeneration; AFFIRM includes systemic inflammatory markers as secondary endpoints. Human clinical validation is pending. Fisetin should not substitute for prescribed anti-inflammatory therapy in autoimmune, rheumatological, or moderate-to-severe inflammatory conditions. For MCAS and allergic inflammation, quercetin has more direct evidence than fisetin. For general anti-inflammaging support, fisetin’s senolytic activity provides a coherent mechanistic case with unresolved clinical validation. For the full context, see our complete clinician’s guide and fisetin vs quercetin article.
Frequently asked questions
Does fisetin help arthritis?
Preclinically, fisetin has anti-inflammatory activity in osteoarthritis chondrocytes and reduces OA progression in mice (3). In humans, one active trial (NCT04210986) is testing this; results are pending.
Can fisetin help with MCAS?
Anecdotally, yes — in the longevity community. Formal human evidence is limited. Quercetin has stronger published evidence for mast cell modulation (6) and is often used first-line.
Is fisetin better than NSAIDs?
No. NSAIDs have strong evidence for acute anti-inflammatory and analgesic effects. Fisetin has a much slower and more modest mechanism. They are not substitutes for one another.
Can I take fisetin with prednisone or DMARDs?
No documented interactions, but formal studies are absent. Discuss with your rheumatology team before combining.
Does fisetin help with fibromyalgia?
No specific evidence. Fibromyalgia involves complex central pain mechanisms that fisetin’s peripheral anti-inflammatory activity would not directly address.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. A Trial of Fisetin to Treat Cartilage Degeneration in Osteoarthritis (NCT04210986). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04210986
3. Zheng W, Feng Z, You S, et al. Fisetin inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes through activating SIRT1 and attenuates the progression of osteoarthritis in mice. Int Immunopharmacol. 2017;45:135-147. https://pubmed.ncbi.nlm.nih.gov/28213268/
4. Kim SC, Kang SH, Jeong SJ, Kim SH, Ko HS, Kim SH. Inhibition of c-Jun N-terminal kinase and nuclear factor kappa B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysaccharide-treated RAW264.7 cells. Immunopharmacol Immunotoxicol. 2012;34(4):645-650. https://pubmed.ncbi.nlm.nih.gov/22217237/
5. Molina N, Bolaños AL, Mercado L, et al. Fisetin decreases the duration of the acute phase of a UVB-induced allergic contact dermatitis in mice. J Photochem Photobiol B. 2020;213:112073. https://pubmed.ncbi.nlm.nih.gov/33176248/
6. Weng Z, Zhang B, Asadi S, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One. 2012;7(3):e33805. https://pubmed.ncbi.nlm.nih.gov/22470478/
7. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037
8. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. https://pubmed.ncbi.nlm.nih.gov/30046148/
9. Verdoorn BP, Evans TK, Hanson GJ, et al. Fisetin for COVID-19 in skilled nursing facilities: senolytic trials in the COVID era. J Am Geriatr Soc. 2021;69(11):3023-3033. https://pmc.ncbi.nlm.nih.gov/articles/PMC8447437/